Value For Italy
By clicking on the menu tabs above, use the map and the interactive sections to discover how AstraZeneca is contributing to the economic growth, research and innovation in Italy
The added value to the Italian economy
For every euro of added value generated in the last 10 years
an additional €2.56 of value is generated in the Italian economy.
The contribution to the Italian GDP generated by the activities of AstraZeneca in the last 10 years
of additional contribution to the GDP over the next 3 years, with 25% estimated growth
For every new AstraZeneca job
jobs have been created in the Italian economy
jobs have been indirectly created by the launch of partnerships and the implementation of supply chains
jobs activated by 2023 (more than double compared to 2020)
about 800 people are directly employed by AstraZeneca in Italy
Employment growth in 5 years
GDP growth contribution
Regional distribution of employees
Economy and Work
Over the last 10 years, AstraZeneca operations in Italy have contributed a total of €5.5 billion to the country's GDP (€308 million in 2020 alone, with an expected €602 million in 2023 through an estimated growth of 25% per annum over the next three years)
For every €1 of direct added value generated by AstraZeneca in Italy over the last 10 years (2010-2020), an additional €2.56 was generated throughout the economy, with a significant multiplier effect on the country's economy
AstraZeneca activated 3,000 jobs in Italy by 2020, with a multiplier effect on direct employment of 4.18: this means that for every person employed by AstraZeneca in Italy (around 800 throughout the country), a further 3.2 jobs are activated in the country's economy (through the launch of partnerships and the operation of supply chains)
Employment growth is higher than the sector and the private sector average, with an increase in the last 5 years of 5.6% and the forecast to activate 6,000 jobs in Italy by 2023 (more than doubled vs. 2020)
AstraZeneca provides quality employment, recognised by the most important international certifications and located throughout the country, with 36.3% of national roles active in southern regions. In addition, the proportion of graduates in the workforce (72%) is almost 20 percentage points higher than the industry average and more than three times the national average.
AstraZeneca also promotes internships that provide a real opportunity to enter the world of work, resulting, in 80% of cases, in employment with the company at the end of the training course (2020 data).
Female employment at AstraZeneca exceeds benchmarks, particularly in managerial roles, with women exceeding 50% of total employees
AstraZeneca is actively involved in therapeutic areas that have the greatest impact in terms of mortality, quality of life and cost for the National Health Service:
Research and Development
Clinical Studies currently launched in Italy
1st company in terms of growth as a percentage of the national total for new studies launched
National leader in lung cancer research (22 studies)
2nd company for growth of number of new clinical studies launched
National leader in ovarian cancer research (12 studies)
Support for independent research
Investments in clinical research
The benefits generated for the National Health System thanks to economic savings and improved care with new drugs*
€1 invested in Italy in clinical studies
generated an additional €4.23 in benefits for the NHS*
Science and Health
RESEARCH AND DEVELOPMENT
AstraZeneca is one of the leading companies
in Italy in terms of its contribution to clinical research in
the country (4th overall), with a higher percentage of
investment per employee than in the industry as a whole,
1st company in terms of growth as a percentage of the national total for new studies launched
2nd company for growth of number of new clinical studies launched Current national leader in clinical research for lung and ovarian cancer (with 22 and 12 ongoing studies respectively)
The clinical studies underway in Italy (currently more than 80) are distributed throughout the country, involving more than 200 centres in 10 regions by 2020, allowing over 2000 patients early access to the most innovative drugs.
In addition, through support for independent research, an additional 21,000 patients in 14 Italian regions have been involved, with over 70 new studies activated.
Thanks to investments in clinical research in Italy (€24 million in 2020, a figure expected to double to €48 million by 2023), AstraZeneca has produced benefits for the NHS in terms of economic savings and improved care with new drugs, corresponding to more than €100 million in 2020: according to a study by Altems, every euro invested in Italy in clinical studies has produced an additional €4.23 in benefits for the system (placing AstraZeneca among the pharmaceutical companies with the highest positive leverage effect generated on the NHS)
SCIENTIFIC SHARING AND COMPARISON
AstraZeneca contribution to scientific knowledge in Italy is substantiated by the continuous growth in the number of publications it has produced (around 200 in the last 5 years), to such an extent that it is recognised by Italian healthcare professionals as one of the leaders in pharmaceutical science for the quality of its interactions, scientific comparisons and sharing, educational programmes and evidence generation.
AstraZeneca support for training and information activities in Italy has triggered more than 30,000 scientific discussions across the country in the last year, in the last ten years reaching over 75,000 healthcare professionals in different regions and building valuable partnerships with leading Italian universities (4-5 new scientific partnerships are expected to be forged each year until 2023).
The Digital Strategy of AstraZeneca provides for the realization of a series of highly innovative projects and services dedicated to patients, with personalized services and support capable of generating relevant benefits for the NHS
AstraZeneca investments in innovation
Patients involved in innovative projects
A path of innovation shared with public, institutional and private partners
The Federation Model is a district that will enable the acceleration of scientific research. Location: MIND, Milano Innovation District
60 research and innovation centres in which AstraZeneca has already implemented innovative projects and solutions
More than 20 Health Innovation Hubs* in the world bringing together digital, R&D and commercial resources to reimagine how we can improve patient outcomes
that produce value for the system thanks to the integration of skills and different visions (AZ + Tech/ Start-ups + Governments/Health Systems)
Incubators and accelerator models for developing innovative solutions through the collaboration of AstraZeneca with many outstanding start-ups
Between AstraZeneca and Governments/Healthcare Systems
Experiential Design Centres
In-house (AstraZeneca Team/Brand) to redefine go-to-market strategies for the company's products, services and experience
External (HCPs/Patients) to study, design and test innovative solutions
AstraZeneca is also managing of digitalization projects at national level. The projects Haya and Ultraspecialist focus on the oncological area.
Haya facilitates the managment of a shared path to care for cancer patients, between doctors and centers, through teleconsultations, telemonitoring and home care solutions. It involves 1000 patients
Ultraspecialists is a teleconsulting platform for patients with ovarian and lung cancer. It involves 70 patients.
AstraZeneca is one of the founding companies of "The Federation Model", a district that will be built within MIND, Milano Innovation District, with the aim of creating optimal solutions to accelerate scientific research in our country and innovation in the various dimensions of people's lives. It will do so by bringing together the various innovative digital projects and solutions activated in more than 60 centres, encouraging public-private partnerships in a virtuous system of innovation on a national scale.
AstraZeneca has established more than 20 Health Innovation Hubs globally to promote new models of interaction between medicine, advanced technologies, patients, healthcare professionals and regulators to reimagine healthcare through sustainability and innovation.
Here's where you can find our global hubs
More than 20 Health Innovation Hubs* in the world pool digital resources, research and development and commercial strategies to reinvent ways of improving treatments.
*The geographical areas pictured in the map are based on AstraZeneca organization structure
Start April 2020
Digital round table
with the presidents of the 24 most important national scientific companies with the Human Technopole Foundation
Digitization and telemedicine, fundamental to promote the continuity of care and monitoring of the health conditions of the most fragile people: to date, there is still no coordination at national level for the development of shared projects
Simplification of processes, which will enable easier access to care (e.g. introduction of digital prescriptions ), but requires systematization of the the procedures for accepting patients
Territorial management of the patient / domiciliation of care, which limits the contagion for those patients who need constant care (e.g. oncology) and has imposed the need to rethink socio-assistance routes
Role of the General Practitioner in the management of chronic diseases, always with a view to promoting more local medicine
Other issues related to the role of scientific information, the organization and staging of congresses, to the contribution of pharmaceutical companies to the evolution of the NHS
The reduction of the environmental impact of its activity represents one of the pillars of the sustainable strategy adopted by AstraZeneca, both in Italy and globally.
Green initiatives currently carried out in Italy
Pillars on which AstraZeneca is basing its sustainability strategy:
less tons of Co2 in the atmosphere
*Achieving net-zero emissions by 2025
**Permanently reducing the emissions (including providers and partners) by 2030
The initiatives launched in Italy
Green Car Project Renewing company cars with hybrid and electric cars to reduce emissions
Converting to eco-friendly stationery and purchasing sustainable printers
Target -15% of air travel for business trips
Environmental sustainability culture
Forests and greenery
AZ Forest project Protecting the forest and planting greenery to offset emissions
Differentiated management of all products
Social activities for employees Park clean-ups (in collaboration with Legambiente)
ISO 14001 Certification Important milestone for a company without production sites
REDUCING THE IMPACT
The reduction of the environmental impact of its activity represents one of the pillars of the sustainable strategy adopted by AstraZeneca globally.
The commitment of the AstraZeneca group and its companies, strongly involved in the social context, is based on a sustainable growth approach as well as on a strong connection between the health of patients, the Group's people and the planet .
THE THREE PILLARS
The sustainability strategy of AstraZeneca is based on three pillars:
- Access to healthcare
- Expanding access to economically sustainable health solutions for treatment and prevention
- Improvement of the therapeutic path through the development of innovative solutions.
- Environmental protection
- Reduction of the environmental impact of company processes and products
- Reaching the Carbon Zero target in 2025
- Protection of the environment and its ecosystems
- Ethics and transparency
- Maintaining high ethical standards and maximum integrity
- Conducting business activities with due competence, accuracy, diligence and fairness